- Home
- IRMD vs ORIC Comparison
IRMD vs ORIC Comparison
Compare IRMD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRMD | ORIC |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.4M | 783.0M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IRMD | ORIC |
|---|---|---|
| Price | $97.93 | $8.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $72.00 | $19.50 |
| AVG Volume (30 Days) | 79.5K | ★ 1.4M |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $80,511,268.00 | N/A |
| Revenue This Year | $15.17 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $59.07 | ★ N/A |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $47.48 | $3.90 |
| 52 Week High | $98.44 | $14.93 |
Technical Indicators
Market Signals| Indicator | IRMD | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 27.80 |
| Support Level | $90.92 | $7.98 |
| Resistance Level | $98.24 | $8.62 |
| Average True Range (ATR) | 2.51 | 0.59 |
| MACD | -0.43 | -0.07 |
| Stochastic Oscillator | 84.71 | 6.52 |
Price Performance
Historical ComparisonAbout IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.